Plus   Neg

Dunelm Q4 Revenues Down, LFL Revenues Up; Sees Weak Profit In FY18 - Quick Facts

Dunelm Group plc (DNLM.L), a homewares retailer, reported Thursday that total group revenues for the fourth quarter dropped 1.4 percent from last year to 236.5 million pounds.

Total like-for-like revenues for the 13-week period ended June 30 edged up 0.1 percent to 209 million pounds. Revenues from LFL stores dropped 4.6 percent, while LFL online revenues climbed 41.8 percent.

Reported gross margin for the quarter will show a year on year decrease of approximately 50bps. Underlying gross margin for the quarter was 40bps higher year on year.

For the year 2018, the Group delivered overall growth of 9.9%.in revenues to 1.05 billion pounds, and LFL revenue growth was 4.2%.

Revenues from LFL stores grew 1 percent and LFL online revenues climbed 37.9 percent.

For the full year, Group gross margin is expected to be 48.0%. This would represent a decline of 90bps over the year, a substantial recovery from the 180bps decline recorded in the first half.

The company expects full year profit before tax, before exceptional items, to be approximately 102 million pounds, down from 109.3 million pounds last year.

For comments and feedback contact: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
MillerCoors LLC has filed a lawsuit against Anheuser-Busch Companies LLC, part of Anheuser-Busch InBev, alleging that Anheuser-Busch's ad campaigns associating MillerCoors' products, Miller Lite and Coor Light, with corn syrup is "false and misleading." During the Super Bowl, ABInBev ran an advertising campaign that mocked Miller Lite and Coors Light use corn syrup in brewing. Shares of Biogen Inc. are falling almost 28 percent in Thursday's trading after the company and Japanese drugmaker Eisai Co. said they will discontinue two late-stage trials for their experimental Alzheimer's drug, Aducanumab. The two Phase 3 trials, ENGAGE and EMERGE, are multi-center, randomized, double-blind, placebo-controlled, parallel-group studies designed to evaluate Aducanumab. The European Union on Wednesday ordered Alphabet Inc.'s Google to pay an antitrust fine of 1.49 billion euros for abusing its dominant position in the online search advertising intermediation market by preventing competition. This is the third antitrust fine by the EU against Google and it represents 1.29 percent of the tech giant's turnover in 2018.
Follow RTT